Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenue	$ 65,179	$ 45,043	$ 34,124
Costs, expenses, and other:
Cost of sales	11,052	8,418	7,082
Research and development	13,337	10,991	9,313
Marketing, selling, and administrative	11,094	8,594	7,404
Acquired in-process research and development	2,910	3,280	3,800
Asset impairment, restructuring, and other special charges	484	861	68
Other—net, (income) expense	571	219	(97)
Costs, expenses, and other	39,448	32,363	27,570
Income before income taxes	25,731	12,680	6,554
Income taxes	5,091	2,090	1,314
Net income	$ 20,640	$ 10,590	$ 5,240
Earnings per share:
Basic (in dollars per share)	$ 23.00	$ 11.76	$ 5.82
Diluted (in dollars per share)	$ 22.95	$ 11.71	$ 5.80
Shares used in calculation of earnings per share:
Basic (in shares)	897.3	900.6	900.2
Diluted (in shares)	899.3	904.1	903.3

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities
Net income	$ 20,640	$ 10,590	$ 5,240
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,997	1,767	1,527
Change in deferred income taxes	(1,707)	(2,683)	(2,341)
Stock-based compensation expense	626	646	629
Gains on sale of product rights	(180)	(224)	(1,879)
Acquired in-process research and development	2,910	3,280	3,800
Other operating activities, net	620	826	319
Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Receivables—(increase) decrease	(7,000)	(2,155)	(2,451)
Inventories—(increase) decrease	(4,671)	(2,507)	(1,425)
Prepaid expenses and other assets—(increase) decrease	(6,609)	(3,331)	(3,453)
Accounts payable and other liabilities—increase (decrease)	10,187	2,609	4,274
Net Cash Provided by Operating Activities	16,813	8,818	4,240
Cash Flows from Investing Activities
Purchases of property and equipment	(7,841)	(5,058)	(3,448)
Proceeds from sales of and distributions from noncurrent investments	964	374	508
Purchases of noncurrent investments	(645)	(677)	(731)
Proceeds from sale of product rights	218	601	1,604
Purchases of in-process research and development	(3,008)	(3,346)	(3,944)
Cash paid for acquisitions, net of cash acquired	(661)	(948)	(1,044)
Other investing activities, net	1	(248)	(98)
Net Cash Used for Investing Activities	(10,972)	(9,302)	(7,153)
Cash Flows from Financing Activities
Dividends paid	(5,384)	(4,680)	(4,069)
Net change in short-term borrowings	(4,338)	(1,852)	4,691
Proceeds from issuance of long-term debt	13,167	11,417	3,959
Repayments of long-term debt	(778)	(664)	0
Purchases of common stock	(4,108)	(2,500)	(750)
Other financing activities, net	(772)	(491)	(335)
Net Cash Provided by (Used for) Financing Activities	(2,213)	1,230	3,496
Effect of exchange rate changes on cash and cash equivalents	372	(297)	169
Net increase in cash and cash equivalents	4,000	449	752
Cash and cash equivalents at beginning of year	3,268	2,819	2,067
Cash and Cash Equivalents at End of Year	$ 7,268	$ 3,268	$ 2,819

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Current Assets
Cash and cash equivalents	$ 7,268	$ 3,268
Accounts receivable	17,760	11,006
Other receivables	2,395	2,270
Inventories	13,744	7,589
Prepaid expenses	14,315	8,341
Other current assets	147	266
Total current assets	55,629	32,740
Noncurrent Assets
Investments	2,802	3,216
Goodwill	5,898	5,770
Other intangibles, net	6,521	6,166
Deferred tax assets	9,959	8,001
Property and equipment, net	24,675	17,102
Other noncurrent assets	6,992	5,720
Total assets	112,476	78,715
Current Liabilities
Short-term borrowings and current maturities of long-term debt	1,635	5,117
Accounts payable	5,379	3,229
Employee compensation	2,375	2,094
Sales rebates and discounts	17,382	11,539
Other current liabilities	8,457	6,397
Total current liabilities	35,228	28,376
Noncurrent Liabilities
Long-term debt	40,868	28,527
Long-term income taxes payable	5,875	4,061
Other noncurrent liabilities	3,970	3,479
Total noncurrent liabilities	50,713	36,067
Commitments and Contingencies
Equity
Common stock—no par value Authorized shares: 3,200.0 Issued shares: 944.8 (2025) and 947.9 (2024)	590	592
Additional paid-in capital	7,346	7,439
Retained earnings	24,470	13,545
Employee benefit trust	(3,013)	(3,013)
Accumulated other comprehensive loss	(2,880)	(4,322)
Other equity	22	31
Total equity	26,535	14,272
Total liabilities and equity	$ 112,476	$ 78,715